Methotrexate and cyclosporine for graft-vs.-host disease prevention: What length of therapy with cyclosporine?

Biology of Blood and Marrow Transplantation

Volumn 3, Issue 4, 1997, Pages 194-201

  Storb, Rainer ^a,b   Leisenring, Wendy ^a   Anasetti, Claudio ^a,b   Appelbaum, Frederick R ^a,b   Deeg, H Joachim ^a,b   Doney, Kristine ^a,b   Martin, Paul ^a,b   Sullivan, Keith M ^a,b   Witherspoon, Robert ^a,b   Pettinger, Mary ^a   Bensinger, William ^a,b   Buckner, C Dean ^a,b   Clift, Reginald ^a   Flowers, Mary E D ^a   Hansen, John A ^a,b   Pepe, Margaret ^a   Chauncey, Thomas ^b,c   Sanders, Jean ^a,b   Thomas, E Donnall ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cyclosporine; Duration of immunosuppression; GVHD prevention; Methotrexate

Indexed keywords

CYCLOSPORIN; METHOTREXATE;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KARNOFSKY PERFORMANCE STATUS; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; TIME; TREATMENT FAILURE;

ADULT; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; KARNOFSKY PERFORMANCE STATUS; METHOTREXATE; MULTIVARIATE ANALYSIS; RECURRENCE; RISK FACTORS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT FAILURE;

EID: 0031243601     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Powles RL, Clink HM, Spence D, Morgenstern G, Watson JG, Selby PJ, Woods M, Barrett A, Jameson B, Sloane J, Lawler SD, Kay HEM, Lawson D, McElwain TJ, Alexander P: Cyclosporine A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet i:327, 1980.
2. Deeg HJ, Storb R, Thomas ED, Flournoy N, Kennedy MS, Banaji M, Appelbaum FR, Bensinger WI, Buckner CD, Clift RA, Doney K, Fefer A, McGuffin R, Sanders JE, Singer J, Stewart P, Sullivan KM, Witherspoon RP: Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 65:1325, 1985.
3. Storb R, Deeg HJ, Thomas ED, Appelbaum FR, Buckner CD, Cheever MA, Clift RA, Doney KC, Flournoy N, Kennedy MS, Lougbran TP, McGuffin RW, Sale GE, Sanders JE, Singer JW, Stewart PS, Sullivan KM, Witherspoon RP: Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood 66:698, 1985.
4. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J, Hill R, Longton G, Lum L, Martin P, McGuffin R, Sanders J, Singer J, Stewart P, Sullivan K, Witherspoon R, Thomas ED: Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 68:119, 1986.
5. Ringdén O, Bäckman L, Lönnqvist B, Heimdahl A, Lindbolm A, Bolme P, Gahrton G: A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplant 1:41, 1986.
6. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Farmer ER, Hess AD, Kaizer H, Mellits D, Sensenbrenner LL, Stuart R, Yeager AM: Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1:21, 1987.
7. Atkinson K, Biggs J, Concannon A, Dodds A, Young S, Wilson F, Ashby M, Downs K: A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy. Aust N Z J Med 21:850, 1991.
8. Ringdén O, Klaesson S, Sundberg B, Ljungman P, Lönnqvist B, Persson U: Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings. Bone Marrow Transplant 9:19, 1992.
9. Ringdén O, Horowitz MM, Sondel P, Gale RP, Biggs JC, Champlin RE, Deeg HJ, Dicke K, Masaoka T, Powles RL, Rimm AA, Rozman C, Sobocinski KA, Speck B, Zwaan FE, Bortin MM: Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 81:1094, 1993.
10. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, Forman SJ: Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329:1225, 1993.
11. Leelasiri A, Greer JP, Stein RS, Goodman S, Brandt SA, Edwards JR, Wolff SN: Graft-versus-host disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone. Bone Marrow Transplant 15:401, 1995.
12. Hows J, Palmer S, Gordon-Smith EC: Cyclosporine and graft failure following bone marrow transplantation for severe aplastic anaemia. Br J Haematol 60:611, 1985.
13. Beelen DW, Quabeck K, Kaiser B, Wiefelspiitz J, Scheulen ME, Graeven U, Grosse-Wilde H, Sayer HG, Schaefer UW: Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation 50:421, 1990.
14. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986.
15. Storb R, Pepe M, Anasetti C, Appelbaum FR, Beatty P, Doney K, Martin P, Stewart P, Sullivan KM, Witherspoon R, Bensinger W, Buckner CD, Clift R, Hansen J, Longton G, Loughran T, Petersen FB, Singer J, Sanders J, Thomas ED: What role for methylprednisolone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 76:1037, 1990.
16. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, Anasetti C, Beatty P, Bensinger WI, Doney K, Hill R, McDonald G, Martin P, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Storb R, Hansen J, Thomas ED: Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission. A randomized trial of two irradiation regimens. Blood 76:1867, 1990.
17. Clift RA, Buckner CD, Appelbaum FR, Bryant E, Bearman SI, Petersen FB, Fisher LD, Anasetti C, Beatty P, Bensinger WI, Doney K, Hill RS, McDonald GB, Martin P, Meyers J, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Storb R, Hansen JA, Thomas ED: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase. A randomized trial of two irradiation regimens. Blood 77:1660, 1991.
18. Appelbaum FR, Barrall J, Storb R, Fisher LD, Schoch G, Ramberg RE, Shulman H, Anasetti C, Bearman SI, Beatty P, Bensinger WI, Buckner CD, Clift RA, Hansen JA, Martin P, Petersen FB, Sanders JE, Singer J, Stewart P, Sullivan KM, Witherspoon RP, Thomas ED: Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Ann Intern Med 112:590, 1990.
19. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD: Bone-marrow transplantation. N Engl J Med 292:832, 1975.
20. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, Clift R, Doney K, Martin PJ, Mickelson E, Nisperos B, O'Quigley J, Ramberg R, Sanders JE, Stewart P, Storb R, Sullivan KM, Witherspoon RP, Thomas ED, Hansen JA: Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 320:197, 1989.
21. Sullivan KM, Agura E, Anasetti C, Appelbaum FR, Badger C, Bearman S, Erickson K, Flowers M, Hansen JA, Loughran T, Martin P, Matthews D, Petersdorf E, Radich J, Riddell S, Ravira D, Sanders J, Schuening F, Siadak M, Storb R, Witherspoon RP: Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28:250, 1991.
22. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York: Wiley, 1980.
23. Pepe MS: Inference for events with dependent risks in multiple endpoint studies. J Am Stat Assoc 86:770, 1991.
24. Hope ACA: A simplified Monte Carlo significance test procedure. J Royal Statist Soc, Series B, 30:582, 1968.
25. Cox DR: Regression models and life tables. J Royal Statist Soc, Series B 34:187, 1972.
26. Storb R, Prentice RL, Sullivan KM, Shulman HM, Deeg HJ, Doney KC, Buckner CD, Clift RA, Witherspoon RP, Appelbaum FR, Sanders JE, Stewart PS, Thomas ED: Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 98:461, 1983.
27. Storb R, Deeg HJ, Pepe M, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J, Hill R, Longton G, Anasetti C, Martin P, Loughran TP, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Thomas ED: Graft-versus-host disease prevention by methotrexate combined with cyclosporine compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol 72:567, 1989.
28. Storb R, Deeg HJ, Pepe M, Appelbaum FR, Anasetti C, Beatty P, Bensinger W, Berenson R, Buckner CD, Clift R, Doney K, Longton G, Hansen J, Hill R, Longhran T, Jr., Martin P, Singer J, Sanders J, Stewart P, Sullivan K, Witherspoon R, Thomas ED: Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 73:1729, 1989.
29. Storb R, Epstein RB, Graham TC, Thomas ED: Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplant 9:240, 1970.
30. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J, Martin P, Sanders JE, Singer J, Thomas ED: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320:828, 1989.
31. Speck B, Gratwohl A, Nissen C, Ruggero D, Cornu P, Osterwalder B, Burri H, Jeannet M: Cyclosporin A for prophylaxis of GVH in clinical bone marrow transplantation. In: SJ Baum, GD Ledney, A Khan (eds) Experimental Hematology Today. Basel: Karger, 117, 1981.
32. Dieterle A, Gratwohl A, Nizze H, Huser B, Mihatsch MJ, Thiel G, Tichelli A, Signer E, Nissen C, Speck B: Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients. Transplantation 49:1093, 1990.